ATE503488T1 - Anti her3 antikörper für die diagnose, prävention und behandlung von hyperproliferativen erkrankungen - Google Patents

Anti her3 antikörper für die diagnose, prävention und behandlung von hyperproliferativen erkrankungen

Info

Publication number
ATE503488T1
ATE503488T1 AT02712879T AT02712879T ATE503488T1 AT E503488 T1 ATE503488 T1 AT E503488T1 AT 02712879 T AT02712879 T AT 02712879T AT 02712879 T AT02712879 T AT 02712879T AT E503488 T1 ATE503488 T1 AT E503488T1
Authority
AT
Austria
Prior art keywords
kinase pathway
diagnosis
prevention
treatment
map kinase
Prior art date
Application number
AT02712879T
Other languages
English (en)
Inventor
Axel Ullrich
Der Horst Edward Van
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8176365&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE503488(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE503488T1 publication Critical patent/ATE503488T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT02712879T 2001-01-31 2002-01-31 Anti her3 antikörper für die diagnose, prävention und behandlung von hyperproliferativen erkrankungen ATE503488T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01102236A EP1228766A1 (de) 2001-01-31 2001-01-31 PYK2 Phosphorylierung durch HER3 induziert Tumorinvasion
PCT/EP2002/001015 WO2002060470A1 (en) 2001-01-31 2002-01-31 Pyk2 phosphorylation by her3 induces tumor invasion

Publications (1)

Publication Number Publication Date
ATE503488T1 true ATE503488T1 (de) 2011-04-15

Family

ID=8176365

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02712879T ATE503488T1 (de) 2001-01-31 2002-01-31 Anti her3 antikörper für die diagnose, prävention und behandlung von hyperproliferativen erkrankungen

Country Status (9)

Country Link
US (1) US20040082510A1 (de)
EP (2) EP1228766A1 (de)
JP (1) JP5652982B2 (de)
AT (1) ATE503488T1 (de)
AU (1) AU2002244692B2 (de)
CA (1) CA2436266A1 (de)
DE (1) DE60239593D1 (de)
ES (1) ES2364128T3 (de)
WO (1) WO2002060470A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
EP1283053A1 (de) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitore der HER3 Aktivität
WO2003101401A2 (en) 2002-06-03 2003-12-11 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
AU2005294347A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
WO2008100624A2 (en) 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
ES2433424T3 (es) * 2008-08-15 2013-12-11 Merrimack Pharmaceuticals, Inc. Métodos y sistemas para predecir respuesta de células frente a un agente terapéutico
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
WO2010108127A1 (en) 2009-03-20 2010-09-23 Genentech, Inc. Bispecific anti-her antibodies
HUE029026T2 (en) 2009-12-22 2017-01-30 Roche Glycart Ag ANTI-HER3 Antibodies and uses thereof
EP2544680B1 (de) 2010-03-11 2015-01-14 Merrimack Pharmaceuticals, Inc. Verwendung von erbb3-hemmern bei der behandlung von dreifach negativem brustkrebs
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
SG11201400150TA (en) 2011-09-30 2014-03-28 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
ES2745684T3 (es) 2011-11-23 2020-03-03 Medimmune Llc Moléculas de unión específicas para HER3 y usos de las mismas
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
EP3087394A2 (de) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarkerprofile zur vorhersage der ergebnisse einer krebstherapie mit erbb3-inhibitoren und/oder chemotherapien
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
IL245861A0 (en) * 2016-05-25 2016-09-04 Yeda Res & Dev Use of substances to treat drug-resistant tumors
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
JP2001505779A (ja) * 1996-12-11 2001-05-08 スージェン・インコーポレーテッド Ｐｙｋ２関連産物および方法
EP1141722A1 (de) * 1998-12-31 2001-10-10 Sugen, Inc. Pyk2 (raftk) und entzündung
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
ES2329437T3 (es) * 1999-06-25 2009-11-26 Genentech, Inc. Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos

Also Published As

Publication number Publication date
CA2436266A1 (en) 2002-08-08
US20040082510A1 (en) 2004-04-29
WO2002060470A1 (en) 2002-08-08
EP1228766A1 (de) 2002-08-07
EP1355658A1 (de) 2003-10-29
DE60239593D1 (de) 2011-05-12
JP5652982B2 (ja) 2015-01-14
JP2004517941A (ja) 2004-06-17
ES2364128T3 (es) 2011-08-25
EP1355658B1 (de) 2011-03-30
AU2002244692B2 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
DE60239593D1 (de) Anti HER3 Antikörper für die Diagnose, Prävention und Behandlung von hyperproliferativen Erkrankungen
DE60042693D1 (de) Dosierung für die behandlung mit anti erbb2-antikörpern
ATE262899T1 (de) Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen
ATE424219T1 (de) Hemmende antikörper der her3-aktivität
HK1078613A1 (zh) 通过抗-erbb2抗体医治非恶性疾病或病患的疗法
DE60124085D1 (de) Pde-v hemmer zur behandlung von morbus parkinson
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
MXPA06012613A (es) Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
BR0213743A (pt) Métodos de tratar ou prevenir mal de alzheimer e uma doença, de tratar um indivìduo que tenha, ou de prevenir que um indivìduo contraia, uma doença ou condição, de inibir a atividade de beta-secretase, a clivagem de um isótipo de protéina precursora de amilóide e a produção de peptìdeo beta amilóide e de placa beta-amilóide em um animal e de produzir um complexo de beta-secretase, uso de um composto e composição
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE69635213D1 (de) Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
WO2024023267A3 (en) Nucleic acid compounds
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
ATE234858T1 (de) Isolierte und verkürzte nukleinsäuremoleküle kodierend für gage-tumorabstossungsantigen
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
ATE142499T1 (de) Verwendung von kreatinphosphat oder phosphoenolbrenztraubensäure zur behandlung von tumoren
ATE372114T1 (de) Verfahren zur erhöhung des testosteronspiegels
DE60037126D1 (de) POLYMORPHISMEN DES MENSCHLICHEN HPXR Gens UND IHRE ANWENDUNG IN DIAGNOSE UND THERAPIE
DE60125148D1 (de) Fctrx genannte proteine und dafür kodierende nuklein säure
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen
ATE464567T1 (de) Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen
DE60027873D1 (de) Moleküle für die behandlung und diagnose von tumoren
DE60225845D1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
DE59609219D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties